Alprazolam
- Generic Name
- Alprazolam
- Brand Names
- Niravam, Xanax
- Drug Type
- Small Molecule
- Chemical Formula
- C17H13ClN4
- CAS Number
- 28981-97-7
- Unique Ingredient Identifier
- YU55MQ3IZY
- Background
Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders. It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole. Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms. Alprazolam's adverse effects are generally related to the sedation it can cause. Alprazolam has been mixed with alcohol as a drug of abuse to potentiate the sedative effects of the drug which may lead to coma and death. Alprazolam was given FDA approval on October 16, 1981.
- Indication
Alprazolam is indicated for the acute treatment of generalized anxiety disorder in adults. Alprazolam is also indicated, either as a standard or extended-release formulation, for the treatment of panic disorder with or without agoraphobia in adults.
Alprazolam may also be prescribed off-label for insomnia, premenstrual syndrome, and depression.
- Associated Conditions
- Generalized Anxiety Disorder, Panic Disorder
Reassessment of Premedication in Surgery
- First Posted Date
- 2012-03-09
- Last Posted Date
- 2013-09-25
- Lead Sponsor
- University Hospital, Angers
- Target Recruit Count
- 455
- Registration Number
- NCT01549691
- Locations
- 🇫🇷
Dept of Anesthesia, Hôpital Foch,, Suresnes, Ile de France, France
🇫🇷Dept of Anesthesia, Hôpital Tenon, Paris, Ile de France, France
🇫🇷Clinique St Leonard, Trélazé, Maine et Loire, France
Effect of Alprazolam on the Success of Inferior Alveolar Nerve (IAN) Block
- Conditions
- Inferior Alveolar Nerve Block Failure
- Interventions
- Drug: placebo
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2012-03-07
- Lead Sponsor
- Isfahan University of Medical Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT01546090
- Locations
- 🇮🇷
School of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran, Islamic Republic of
Effects of Buspar on Depressive Symptom Improvement and Neuroprotection in Patients With Anxiety Disorder
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2015-05-20
- Lead Sponsor
- Seoul National University Hospital
- Registration Number
- NCT01546896
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Premedication With Melatonin and Alprazolam Combination Versus Alprazolam or Melatonin Alone
- Conditions
- Anxiety
- Interventions
- Drug: placeboDrug: meloset (melatonin)
- First Posted Date
- 2011-12-06
- Last Posted Date
- 2012-10-05
- Lead Sponsor
- B.P. Koirala Institute of Health Sciences
- Target Recruit Count
- 80
- Registration Number
- NCT01486615
- Locations
- 🇳🇵
Dr Krishna Pokharel, Dharan, Koshi, Nepal
🇳🇵B. P. Koirala Institute of Health Sciences, Dharan, Koshi, Nepal
An Bioequivalence Study Of Xanax Extended Release Tablets From Two Different Manufacturing Sites
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2011-04-07
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT01330472
- Locations
- 🇸🇬
Pfizer Investigational Site, Singapore, Singapore
A Bioequivalence Study Of A New Alprazolam Dropped Formulation Versus Alprazolam Tablets
- First Posted Date
- 2011-03-25
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01322867
- Locations
- 🇧🇷
ICF - Instituto de Ciencias Farmaceuticas, Aparecida de Goiania, GO, Brazil
Bioequivalence of a New and a Commercial Alprazolam Sublingual Formulation
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2011-01-28
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Registration Number
- NCT01285505
Pharmacokinetics Of Alprazolam Sublingual Tablet Versus Conventional Tablet
- Conditions
- Anxiety Disorder
- Interventions
- First Posted Date
- 2010-12-08
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT01256151
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting Conditions
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2010-08-25
- Last Posted Date
- 2010-08-25
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT01188031
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Non-Fasting Conditions
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2010-08-25
- Last Posted Date
- 2010-08-25
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT01188057
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.